Abstract:Background: Diabetes mellitus is the third-largest non-communicable chronic disease worldwide. There are many effective drugs, but the long-term use of these clinical drugs may cause various side effects. Therefore, it is urgent to develop new antidiabetic molecules with higher efficacy and lower toxicity. Methods: Fifteen new 3-aryl-1-(5-methylisoxazol-3-ylamino)-1-(4-nitrophenyl)propan-1-one were synthesized directly through the Mannich reaction of 4-nitroacetophenone, 3-amino-5- methylisoxazole and aromatic aldehydes catalyzed by concentrated hydrochloric acid. The molecular structures of the products were fully characterized by 1H NMR, 13C NMR, ESI MS and HRMS. The peroxisome proliferator-activated receptor (PPAR) response element and α-glucosidase inhibitory activity of these compounds were evaluated in vitro. Molecular docking, molecular physical parameters calculation, and molecular toxicity prediction were performed to analyze the structure- activity relationship and evaluate the druggability of these compounds theoretically. Results: All compounds exhibited weak antidiabetic activities, but compound 15 showed promising as a high performance, dual-target antidiabetic lead compound with peroxisome proliferatoractivated receptor (PPAR) response element relative agonist activity of 99.55% at 27.2 nmol·mL−1 and α-glucosidase inhibitory activity of 35.21% at 13.6 nmol·mL−1. All compounds obtained may have no cardiotoxicity, no acute toxicity, no carcinogenic, and within safe range of mutagenic risk. Conclusion: This study identified a potential PPAR lead molecule and presented an unusual strategy for antidiabetic drug development.

Design, Synthesis and Biological Evaluation of Cajanonic Acid A Analogues As Potent PPAR Γ Antagonists

Synthesis and Biological Evaluation of Cajanonic Acid A Derivatives As Potential PPARγ Antagonists.

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.

Identification of Novel PPARα/γ Dual Agonists by Virtual Screening, ADMET Prediction and Molecular Dynamics Simulations.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Tryptophan-Containing Dipeptide Derivatives As Potent Ppar Gamma Antagonists: Design, Synthesis, Biological Evaluation, And Molecular Modeling

Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation

Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ

Design, Synthesis, and Evaluation of Novel L-Phenylglycine Derivatives As Potential PPARγ Lead Compounds

Scaffold-based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors.

Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones As Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents

Identification of a Novel Selective Agonist of PPARγ with No Promotion of Adipogenesis and Less Inhibition of Osteoblastogenesis

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Identification of Novel PPARα/γ Dual Agonists by Pharmacophore Screening, Docking Analysis, ADMET Prediction and Molecular Dynamics Simulations.

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators

Design, molecular docking and dynamics simulations of PPARs pan agonists

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

A Novel Dual Peroxisome Proliferator-Activated Receptors Α and Γ Agonist with Beneficial Effects on Insulin Resistance and Lipid Metabolism

Synthesis and Investigation on the Antidiabetic Effect of 3-Aryl-1-(5-methylisox Azol-3-ylamino)-1-(4-nitrophenyl) Propan-1-one